Comparison of Systemic Toxicities of 177Lu-DOTMP and 153Sm-EDTMP Administered Intravenously at Equivalent Skeletal Doses to Normal Dogs

Journal of Nuclear Medicine Technology

Linda M. Berent¹  Dae Young Kim¹  Carolyn J. Henry¹  Jimmy C. Lattimer¹  Margaret E. Bryan¹  David Bommarito¹  Cathy Cutler¹  Hendrik Engelbrecht¹  Alan Ketring¹  Jeffrey N. Bryan¹ 

关键词: ¹⁷⁷Lu-DOTMP;    dogs;    bone tumors;    bone-seeking radiopharmaceuticals;   

DOI  :  10.2967/jnmt.108.054700

学科分类：医学（综合）

来源: Society of Nuclear Medicine

【 摘 要 】

Bone-seeking radiopharmaceuticals have been used to effectively treat cancer arising from and metastasizing to bone in humans and dogs. The rate of complete tumor control is low, and the geographic distribution of available compounds is limited by their half-lives. This experiment was done to evaluate in normal dogs the toxicity of 177Lu-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetramethylene phosphonate (177Lu-DOTMP) used as a potential therapeutic radiopharmaceutical. Methods: Four normal purpose-bred dogs were administered 177Lu-DOTMP at a dose of 8.14 MBq/kg and monitored for 84 d for evidence of toxicity in the bone marrow and vital organs. Results: No statistically significant alterations in the biochemical profile, white blood cell count, or platelet count were observed in any dog. Very mild decreases in the red cell count were seen on day 84. No microscopic evidence of toxicity was present at necropsy. Conclusion: The dogs receiving 177Lu-DOTMP tolerated the administration and the effects of the compound without apparent clinical toxicity. The results of this experiment support the further evaluation in tumor-bearing dogs of 177Lu-DOTMP as a potential therapy for metastatic bone cancer and primary bone tumors in humans and dogs.

【 授权许可】

Unknown